Projected sales at risk due to patent expiry 2009-2022

Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)

Projected sales at risk due to patent expiry 2009-2022 This statistic depicts small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022. According to the data, in 2009, 17.8 billion U.S. dollars were at risk due to loss of exclusivity.
Show more

Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)

Loading statistic...
Sales in billion U.S. dollars
200917.8
201015.7
201117.9
201223.8
201314
201411.1
201520.6
201614.8
2017*22.8
201829
201912.6
202011.7
20215.2
202214
Sales in billion U.S. dollars
200917.8
201015.7
201117.9
201223.8
201314
201411.1
201520.6
201614.8
2017*22.8
201829
201912.6
202011.7
20215.2
202214
Download Settings Share
Download started
Please be patient - this may take a moment
This statistic depicts small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022. According to the data, in 2009, 17.8 billion U.S. dollars were at risk due to loss of exclusivity.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Global pharmaceutical industry
Global pharmaceutical industry

All Information
in one Presentation

Global pharmaceutical industry

Everything On "Global pharmaceutical industry" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Generics and biosimilars"
  • Global overview
  • Top companies
  • U.S. market
  • Patent expiration
  • Savings
  • Biosimilars
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.

Menu